Aclaris Therapeutics (ACRS) Guggenheim Securities Emerging Outlook: Biotech Summit 2026 summary

Pipeline overview and development updates

• Focus on large and small molecule therapeutics, including TSLP monoclonal antibody and bispecifics, with key readouts expected in late 2026.

• TSLP monoclonal antibody in a 90-patient phase II study for atopic dermatitis, aiming for best-in-class efficacy and potential for extended dosing intervals of 2-3 months.

• Bispecific antibody targeting TSLP and IL-4R demonstrated a 26-day half-life and strong target engagement in healthy volunteers, with phase 1b studies in AD and asthma underway.

• Oral ITK/JAK3 inhibitor (ATI-2138) showed strong efficacy and safety in atopic dermatitis, with lead indication selection imminent.

• Next-generation ITK-selective compounds, including ITK/TXK variants, are advancing toward IND filings, with clinical entry expected in the coming months.

Clinical and mechanistic insights

• TSLP antibody outperformed Tezspire in potency and showed high EASI-75 and IGA 0/1 rates in prior studies, supporting its advancement.

• Bispecific approach aims for deeper and broader efficacy by targeting both TSLP and IL-4R, addressing both T2 high and T2 low asthma and atopic dermatitis populations.

• Injection site reactions were the most common adverse event for the bispecific, but were mild, transient, and not dose-related.

• Phase 1b studies in severe AD and moderate asthma are designed for robust PK/PD and efficacy readouts, with endpoints aligned to industry standards.

• ITK inhibitors leverage covalent binding for selectivity and potency, overcoming historical challenges with reversible inhibitors.

Competitive positioning and future outlook

• ITK/JAK3 inhibitor ATI-2138 demonstrated balanced, potent activity and favorable safety, with potential differentiation from existing JAK inhibitors.

• Indications under consideration include alopecia and lichen planus, with head-to-head data suggesting superior efficacy versus ritlecitinib.

• Next-gen ITK-selective compounds offer flexibility to target Th2/Th17 or Th1 biology, broadening potential indications.

• Safety profile of ITK inhibitors is expected to be favorable, with less global immunosuppression compared to other JAK inhibitors.

• Oral small molecules are positioned as complementary to biologics, with significant market opportunity across multiple immune-mediated diseases.